Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501

SAN JOSE, Calif., July 19, 2019 -- (Healthcare Sales & Marketing Network) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulat... Biopharmaceuticals, Regulatory Aridis Pharmaceuticals, gallium citrate, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news